Guzman Y Gomez: It’s not just the burritos that are expensive, so is the stock!

The Guzman Y Gomez IPO was a success, but the stock is expensive

Stuart Roberts from Stocks Down Under gives his take on the newly public company, Guzman Y Gomez (ASX: GYG). He admits to being a patron himself but expresses concern over the company’s high valuation, comparing it to Domino’s (ASX: DMP) and highlighting its pricey quick service restaurant format. Despite the restaurant chain being well-executed, Stuart considers it overpriced, and anticipates more decline after an initial drop of 5%.

Stuart further discusses the vulnerability of the company in the face of consumer shifts like those seen with Domino’s (ASX: DMP). He remarks that cost of living pressures can redirect customers to long-standing reliable outlets such as McDonald’s. Stuart also feels sceptical of Guzman’s (ASX: GYG) high-growth projections given their current climate of consumer sentiment and living costs.

Better value in Life Sciences

Lastly, Stuart brings attention to Botanix Pharmaceuticals (ASX: BOT), a company he finds lacks the recognition it deserves despite its FDA approved drug for an underserved medical condition. He encourages investors who profited from Guzman (ASX: GYG) to consider investing in Botanix Pharmaceuticals (ASX: BOT). Despite acknowledging the potential for Guzman’s (ASX: GYG) success, as was the unexpected case for Starbucks years ago, Stuart maintains his reservations about the company’s valuation.

Watch the full interview here!

What are the Best ASX Fast Food Stocks to invest in right now?

Check our ASX buy/sell tips